Cantor Fitzgerald began coverage on shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in a report released on Thursday, June 29th, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $137.00 price target on the medical equipment provider’s stock.
Several other analysts have also issued reports on ZBH. Needham & Company LLC lifted their target price on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a strong-buy rating in a research report on Friday, April 28th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a hold rating to a sell rating in a research report on Tuesday, April 4th. Oppenheimer Holdings, Inc. set a $132.00 target price on shares of Zimmer Biomet Holdings and gave the company a buy rating in a research report on Friday, April 28th. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They issued a sell rating and a $92.00 target price on the stock. Finally, Royal Bank Of Canada reiterated a buy rating and issued a $133.00 target price on shares of Zimmer Biomet Holdings in a research report on Tuesday, March 14th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $138.36.
Zimmer Biomet Holdings (ZBH) traded down 1.32% on Thursday, reaching $123.78. The company had a trading volume of 1,523,106 shares. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The company’s 50 day moving average is $127.89 and its 200-day moving average is $121.20. The firm has a market capitalization of $24.98 billion, a price-to-earnings ratio of 35.25 and a beta of 1.21.
Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.02 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings will post $8.36 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/07/29/cantor-fitzgerald-begins-coverage-on-zimmer-biomet-holdings-inc-zbh-updated-updated-updated.html.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Investors of record on Friday, June 23rd were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is currently 27.59%.
In related news, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 6,200 shares of the company’s stock in a transaction on Friday, May 5th. The shares were sold at an average price of $116.76, for a total transaction of $723,912.00. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Cibc World Markets Corp boosted its position in shares of Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock worth $2,565,000 after buying an additional 7,269 shares during the period. Norges Bank bought a new position in shares of Zimmer Biomet Holdings during the fourth quarter worth about $234,271,000. Thrivent Financial for Lutherans boosted its position in shares of Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock worth $737,000 after buying an additional 450 shares during the period. GLG LLC boosted its position in shares of Zimmer Biomet Holdings by 6.8% in the fourth quarter. GLG LLC now owns 10,058 shares of the medical equipment provider’s stock worth $1,038,000 after buying an additional 639 shares during the period. Finally, Auxier Asset Management boosted its position in shares of Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock worth $8,928,000 after buying an additional 2,750 shares during the period. Hedge funds and other institutional investors own 84.37% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.